期刊文献+

金龙胶囊联合DCF方案治疗进展期胃癌疗效观察 被引量:4

下载PDF
导出
摘要 目的:评价DCF方案配合金龙胶囊治疗进展期胃癌的客观疗效及不良反应。方法:65例进展期胃癌病人按随机信封法分成金龙组和对照组,金龙组采用DCF化疗方案联合金龙胶囊,对照组仅采用DCF方案。结果:金龙组有效率为42.3%,疾病控制率75.0%,PD率25.4%。对照组有效率为38.3%,疾病控制率73.0%,PD率27.0%。金龙组有效率及疾病控制率高于对照组,但两组比较无统计学意义(P>0.05),金龙组PD率低于对照组,两组比较有统计学意义(P<0.05)。金龙组一般症状改善优于对照组,金龙组在骨髓抑制、虚弱、厌食、恶心、呕吐及粘膜炎毒副反应发生率低于对照组,二组比较有统计学意义(P<0.05),在神经毒性、感染及腹泻方面有减轻毒副反应的趋势,但没有统计学意义(P>0.05)。结论:金龙胶囊联合DCF方案治疗进展期胃癌,提高了化疗有效率,减轻化疗相关不良反应,改善患者体能状况,值得进一步临床研究。
出处 《甘肃科技》 2008年第10期152-153,共2页 Gansu Science and Technology
  • 相关文献

参考文献2

二级参考文献11

  • 1沈琳,李洁,张晓东,李燕,张小田,金懋林.PELF方案治疗进展期胃癌68例[J].中国肿瘤临床,2005,32(3):162-164. 被引量:19
  • 2[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
  • 3[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
  • 4[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
  • 5[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43
  • 6[7]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660
  • 7[9]Cunningham D,Rao S,Starling N,et al.Randomised multicentie phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patientswith advanced oesophagogastric cancer:The REAL 2 trial.Proc Am Soc Clin Oncol,2006,24:182S
  • 8[10]Park Y,Lee J,Ryoo B,et al.Aphase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.Proc Am Soc Clin Oncol,2006,24:197S
  • 9[11]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophagealjunction adenocarcin oma:Final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2000,20:531
  • 10[12]Bouche O,Raoul J,Giovanini M,et al.Randomized phase Ⅱ trial of LV5FU2,LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA):Final results of study FFCD9803,Proc Am Soc Clin Oncol,2003,21,1033

共引文献84

同被引文献109

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部